Breakthroughs in tuberculosis vaccine and drug development pave way for global health advancements

Despite decades of efforts, tuberculosis remains a global health crisis, claiming over 1.3 million lives annually. In a comprehensive review published in Molecular Biomedicine, an international team of researchers unveils groundbreaking progress in TB vaccine development and therapeutic innovations, offering hope to curb the disease’s devastating impact.

The study emphasizes the limitations of the century-old Bacille Calmette-Guérin (BCG) vaccine, which fails to prevent adult pulmonary TB or latent infections. To overcome this, researchers are exploring next-generation strategies, including multi-antigen vaccines and mRNA-based platforms, currently in clinical trials. Notable candidates like GamTBvac (a subunit vaccine) and viral vector-based MVATG18598 show promise in enhancing immune responses and shortening treatment regimens.

Artificial intelligence (AI) and bioinformatics are revolutionizing TB research. Tools like AlphaFold predict protein structures with atomic precision, accelerating antigen design. “AI helps us identify hidden patterns in pathogen biology, enabling faster, smarter vaccine development,” explains Dr. Wenping Gong, senior author of the study.

Kansas City combats one of the worst tuberculosis outbreaks in recent US history

Two patients have died since spread of disease was identified in January 2024, reports Alan Booth, Senior Editor at International Labmate Kansas in the United States has been experiencing o... Read More

The review also spotlights novel therapies for drug-resistant TB, such as bedaquiline and delamanid, which target unique bacterial pathways. Host-directed therapies (HDT), which modulate human immune responses to weaken TB persistence, are emerging as complementary strategies.

Challenges remain, including antigen diversity, diagnostic gaps, and accessibility in low-resource regions. However, over 80 TB antigens have been identified, with 12 prioritized for vaccine development. Clinical trials for inactivated vaccines like RUTI and mRNA candidates like BNT164 are underway, aiming to address both active and latent infections.

“Our goal is to translate lab discoveries into real-world solutions,” says Dr. Gong. “Combining AI, global collaboration, and innovative trial designs will be key to meeting the WHO’s 2035 TB eradication target.”

For further reading please visit: 10.1186/s43556-024-00243-6